» Articles » PMID: 9444958

Gab1 Coupling to the HGF/Met Receptor Multifunctional Docking Site Requires Binding of Grb2 and Correlates with the Transforming Potential

Overview
Journal Oncogene
Date 1998 Jan 28
PMID 9444958
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Activation of the HGF receptor, encoded by the c-MET protooncogene (Met receptor), triggers motility, matrix-invasion and branching morphogenesis in epithelial cells. It has recently been shown that the Met receptor interacts with Gab-1, an IRS-like adaptor protein, via the docking site (Y1349VHVNATY1356VNV) known to bind Grb2 and multiple SH2-containing signal transducers. Here we show that Gab1 is the major phosphorylation-substrate of the Met receptor and of its oncogenic variant Tpr-Met. A series of point mutations in the docking site established a direct correlation between the ability to recruit and phosphorylate Gab1 and the transforming potential. Interestingly, the mutations of either Y1356 or N1358 abolished the binding of both Grb2 and Gab1 in intact cells. Furthermore, peptides designed to block either the SH2 or the SH3 domains of Grb2 interfered with the receptor-Gab1 interaction. These data indicate that Gab1 coupling to the Met receptor requires binding of Grb2 and correlates with the transforming potential of Tpr-Met.

Citing Articles

Recording and classifying MET receptor mutations in cancers.

Guerin C, Tulasne D Elife. 2024; 13.

PMID: 38652103 PMC: 11042802. DOI: 10.7554/eLife.92762.


Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance.

Mazumder S, Higgins P, Samarakoon R Cancers (Basel). 2023; 15(4).

PMID: 36831657 PMC: 9953937. DOI: 10.3390/cancers15041316.


B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer.

Pathmanathan S, Yao Z, Coelho P, Valla R, Drecun L, Benz C iScience. 2022; 25(11):105419.

PMID: 36388990 PMC: 9646953. DOI: 10.1016/j.isci.2022.105419.


Physiological Signaling and Structure of the HGF Receptor MET.

Baldanzi G, Graziani A Biomedicines. 2017; 3(1):1-31.

PMID: 28536396 PMC: 5344233. DOI: 10.3390/biomedicines3010001.


Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.

Kumar D, Kandl C, Hamilton C, Shnayder Y, Tsue T, Kakarala K JAMA Otolaryngol Head Neck Surg. 2015; 141(12):1133-9.

PMID: 26540318 PMC: 4815928. DOI: 10.1001/jamaoto.2015.2381.